ライフサイエンスコーパス: pneumococcal polysaccharide vaccine

1 with the conjugate vaccine compared with the pneumococcal polysaccharide vaccine.

2 re due to serotypes covered by the 23-valent pneumococcal polysaccharide vaccine.

3 were serotypes represented in the 23-valent pneumococcal polysaccharide vaccine.

4 lysaccharides used to formulate a polyvalent pneumococcal polysaccharide vaccine.

5 ates were serotypes that are included in the pneumococcal polysaccharide vaccine.

6 9F, and 23F linked to CRM197, or a 23-valent pneumococcal polysaccharide vaccine.

7 long-lasting, impaired antibody responses to pneumococcal polysaccharide vaccines.

8 the influence of Km and Gm allotype genes on pneumococcal polysaccharide vaccines.

9 ons manifest decreased antibody responses to pneumococcal polysaccharide vaccines.

10 A 23-valent unconjugated pneumococcal polysaccharide vaccine (23vP), routinely ad

11 7; Prevnar) in infancy followed by 23-valent pneumococcal polysaccharide vaccine (23vPPV; Pneumovax)

12 -treated patients had decreased responses to pneumococcal polysaccharide vaccine (57% of patients had

13 uded in the 7-valent conjugate and 23-valent pneumococcal polysaccharide vaccines accounted for 78 pe

14 s, but it remains unclear whether use of the pneumococcal polysaccharide vaccine alters the overall r

15 697 received 23-valent pneumococcal polysaccharide vaccine and 695 received pla

16 rgeting high-risk groups was undertaken with pneumococcal polysaccharide vaccine, and subsequently ra

17 All children received 23-valent pneumococcal polysaccharide vaccine at age 13 months.

18 Four of 16 patients in group 1 responded to pneumococcal polysaccharide vaccine compared with 14 of

19 Immunization with the pneumococcal polysaccharide vaccine does not prevent col

20 The pneumococcal polysaccharide vaccine elicited comparable

21 se findings support the effectiveness of the pneumococcal polysaccharide vaccine for the prevention o

22 Pneumococcal polysaccharide vaccine is recommended for e

23 However, the effect of pneumococcal polysaccharide vaccine on vascular events r

24 gate vaccine followed by 1 dose of 23-valent pneumococcal polysaccharide vaccine or a single dose of

25 rted that the 7-valent diphtheria-conjugated pneumococcal polysaccharide vaccine (PCV7) is safe and i

26 administration of the heptavalent conjugated pneumococcal polysaccharide vaccine (PCV7) were also ass

27 We compared revaccination with 23-valent pneumococcal polysaccharide vaccine (PN23) with primary

28 vaccination or revaccination with 23-valent pneumococcal polysaccharide vaccine (PN23).

29 ther passive immunization with the 23-valent pneumococcal polysaccharide vaccine (Pneumovax(R) 23; PP

30 The 23-valent pneumococcal polysaccharide vaccine (Pneumovax) might pr

31 udy murine immune responses to the 23-valent pneumococcal polysaccharide vaccine Pnu-Imune, both in v

32 All received 23-valent pneumococcal polysaccharide vaccine (PPS).

33 dose 6 months later, and 1 dose of 23-valent pneumococcal polysaccharide vaccine (PPSV23) 1 month lat

34 gate vaccine (PCV13) compared with 23-valent pneumococcal polysaccharide vaccine (PPSV23) among US ad

35 ortions and incidence matching the 23-valent pneumococcal polysaccharide vaccine (PPSV23) and 13-vale

36 usly vaccinated with >/= 1 dose of 23-valent pneumococcal polysaccharide vaccine (PPSV23) and had CD4

37 tion Practices has recommended the 23-valent pneumococcal polysaccharide vaccine (PPSV23) for nonelde

38 PD), with the effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) for prevent

39 Although the 23-valent pneumococcal polysaccharide vaccine (PPSV23) protects ag

40 Controversy persists over the benefits of pneumococcal polysaccharide vaccine (PPV) for adults at

41 Revaccination of healthy adults with pneumococcal polysaccharide vaccine (PPV) within several

42 Twenty-three-valent pneumococcal polysaccharide vaccine (PPV-23), which cont

43 umonia (n = 16) and healthy volunteers given pneumococcal polysaccharide vaccine (PPV; n = 14) or pne

44 determine the effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPV23) among Navajo

45 The benefits of using the 23-valent pneumococcal polysaccharide vaccine (PPV23) are controve

46 grouped serotypes contained in the 23-valent pneumococcal polysaccharide vaccine (PPV23) decreased at

47 Since the 23-valent pneumococcal polysaccharide vaccine (PPV23) is less effe

48 In the United Kingdom, the 23-valent pneumococcal polysaccharide vaccine (PPV23) is recommend

49 >/= 200 randomized to receive the 23-valent pneumococcal polysaccharide vaccine (PPV23) or placebo a

50 and are indications for receipt of 23-valent pneumococcal polysaccharide vaccine (PPV23).

51 althy human adults with Pneumovax (23-valent pneumococcal polysaccharide vaccine [PPV23]), IgG anti-c

52 licensed (23-valent, 25 microgram/serotype) pneumococcal polysaccharide vaccine (PV).

53 The 23-valent pneumococcal polysaccharide vaccine was formulated to pr

54 rs after transplantation and the response to pneumococcal polysaccharide vaccine was significantly lo

55 sera of people immunized with the 23-valent pneumococcal polysaccharide vaccine, we confirmed that h

56 ne response to that induced by the 23-valent pneumococcal polysaccharide vaccine, which has been the

57 eritoneal B1b compartment, immunization with pneumococcal polysaccharide vaccine yielded comparable a